Claims
- 1. A compound of the formula:
- 2. The compound of claim 1, wherein X″ is nitrogen.
- 3. The compound of claim 1, wherein X′ and X″ are nitrogen.
- 4. The compound of claim 1, wherein j is 0, 1, or 2.
- 5. The compound of claim 1, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.
- 6. The compound of claim 1, wherein Cx is selected from the group consisting of:
- 7. The compound of claim 6, wherein Y, Y′, Y″ and Y′″ all are carbon bonded to a substituent species.
- 8. The compound of claim 6, wherein one or two of Y, Y′, Y″ and Y′″ are nitrogen and the remaining are carbon bonded to a substituent species.
- 9. The compound of claim 6, wherein E′, E″ and E′″ all are carbon bonded to substituent species.
- 10. The compound of claim 6, wherein one or two of E′, E″ and E′″ are nitrogen and the remaining are carbon bonded to substituent species.
- 11. The compound of claim 1, selected from the group consisting of (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo [2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3-thienyl)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane.
- 12. A compound of the formula:
- 13. The compound of claim 12, wherein X″ is nitrogen.
- 14. The compound of claim 12, wherein X′ and X″ are nitrogen.
- 15. The compound of claim 12, wherein j is 0, 1 or 2.
- 16. The compound of claim 12, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.
- 17. The compound of claim 12, wherein Cx is selected from the group consisting of:
- 18. The compound of claim 17, wherein Y, Y′, Y″ and Y′″ all are carbon bonded to a substituent species.
- 19. The compound of claim 17, wherein one or two of Y, Y′, Y″ and Y′″ are nitrogen and the remaining are carbon bonded to a substituent species.
- 20. The compound of claim 17, wherein E′, E″ and E′″ all are carbon bonded to substituent species.
- 21. The compound of claim 17, wherein one or two of E′, E″ and E′″ are nitrogen and the remaining are carbon bonded to substituent species.
- 22. A pharmaceutical composition useful for treatment of central nervous system disorders comprising a therapeutically effective amount of a compound of the formula:
- 23. The pharmaceutical composition of claim 22, wherein X″ is nitrogen.
- 24. The pharmaceutical composition of claim 22, wherein X′ and X″ are nitrogen.
- 25. The pharmaceutical composition of claim 22, wherein j, is 0, 1, or 2.
- 26. The pharmaceutical composition of claim 22, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.
- 27. The pharmaceutical composition of claim 22, wherein Cx is selected from the group consisting of:
- 28. The pharmaceutical composition of claim 27, wherein Y, Y′, Y″ and Y′″ all are carbon bonded to a substituent species.
- 29. The pharmaceutical composition of claim 27, wherein one or two of Y, Y′, Y″ and Y′″ are nitrogen and the remaining are carbon bonded to a substituent species.
- 30. The pharmaceutical composition of claim 27, wherein E′, E″ and E′″ all are carbon bonded to substituent species.
- 31. The pharmaceutical composition of claim 27, wherein one or two of E′, E″ and E′″ are nitrogen and the remaining are carbon bonded to substituent species.
- 32. The pharmaceutical composition of claim 27, wherein the compound is selected from the group consisting of (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3-thienyl)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane.
- 33. A pharmaceutical composition useful for treatment of central nervous system disorders comprising a therapeutically effective amount of a compound of the formula:
- 34. The pharmaceutical composition of claim 33, wherein X″ is nitrogen.
- 35. The pharmaceutical composition of claim 33, wherein X′ and X″ are nitrogen.
- 36. The pharmaceutical composition of claim 33, wherein j is 0, 1, or 2.
- 37. The pharmaceutical composition of claim 33, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.
- 38. The pharmaceutical composition of claim 33, wherein Cx is selected from the group consisting of:
- 39. The pharmaceutical composition of claim 38, wherein Y, Y′, Y″ and Y′″ all are carbon bonded to a substituent species.
- 40. The pharmaceutical composition of claim 38, wherein one or two of Y, Y′, Y″ and Y′″ are nitrogen and the remaining are carbon bonded to a substituent species.
- 41. The pharmaceutical composition of claim 38, wherein E′, E″ and E′″ all are carbon bonded to substituent species.
- 42. The pharmaceutical composition of claim 38, wherein one or two of E′, E″ and E′″ are nitrogen and the remaining are carbon bonded to substituent species.
- 43. A method of treating central nervous system disorders comprising of administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:
- 44. The method according to claim 43, wherein X″ is nitrogen.
- 45. The method according to claim 43, wherein X′ and X″ are nitrogen.
- 46. The method according to claim 43, wherein j is 0, 1, or 2.
- 47. The method according to claim 43, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.
- 48. The method according to claim 43, wherein Cx is selected from the group consisting of:
- 49. The method according to claim 43, wherein Y, Y′, Y″ and Y′″ all are carbon bonded to a substituent species.
- 50. The method according to claim 48, wherein one or two of Y, Y′, Y″ and Y′″ are nitrogen and the remaining are carbon bonded to a substituent species.
- 51. The method according to claim 48, wherein E′, E″ and E′″ all are carbon bonded to substituent species.
- 52. The method according to claim 48, wherein one or two of E′, E″ and E′″ are nitrogen and the remaining are carbon bonded to substituent species.
- 53. The method according to claim 48, wherein the compound is selected from the group consisting of (1S,4S)-2-(5-(3-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-methoxyphenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(4-fluorophenoxy)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane, (1S,4S)-2-(5-(3-thienyl)-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane and (1S,4S)-2-(5-benzoyl-3-pyridyl)-2,5-diazabicyclo[2.2.1]heptane.
- 54. A method of treating central nervous system disorders comprising of administering to a subject in need thereof a therapeutically effective amount of a compound of the formula:
- 55. The method of claim 54, wherein X″ is nitrogen.
- 56. The method of claim 54, wherein X′ and X″ are nitrogen.
- 57. The method of claim 54, wherein j is 0, 1 or 2.
- 58. The method of claim 54, wherein the values of u, v, w, x and y are selected to provide a 7-, 8- or 9-membered diazabicyclic ring.
- 59. The method of claim 54, wherein Cx is selected from the group consisting of:
- 60. The method of claim 59, wherein Y, Y′, Y″ and Y′″ all are carbon bonded to a substituent species.
- 61. The method of claim 59, wherein one or two of Y, Y′, Y″ and Y′″ are nitrogen and the remaining are carbon bonded to a substituent species.
- 62. The method of claim 59, wherein E′, E″ and E′″ all are carbon bonded to substituent species.
- 63. The method of claim 59, wherein one or two of E′, E″ and E′41 are nitrogen and the remaining are carbon bonded to substituent species.
RELATED APPLICATION
[0001] This application claims priority from U.S. patent application Ser. No. 09/578,768, filed May 25, 2000, the disclosure of which is incorporated by reference herein in its entirety.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09578768 |
May 2000 |
US |
Child |
09864905 |
May 2001 |
US |